Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).

Clarisse MarcombesLaetitia PensoAlain WeillRosemary Dray-SpiraMahmoud ZureikEmilie Sbidian

Published in: The British journal of dermatology (2023)

This real-life study suggested longer persistence of IL23i than TNFi, IL17i and the IL12/23i in second-line treatment for psoriasis. Persistence rates for all biologics remained low at 3 years.

Keyphrases

health insurance
rheumatoid arthritis
affordable care act
emergency department
healthcare
adverse drug